65,437 trials
Malignant Neoplasm · Metastatic Malignant Neoplasm in the Bone · Pain
Primary: Re-Treatment Rates - Arm 1 (8 Gy x 1) vs. Arm 2 (8 Gy x 2) — 3; 3; 19; 17 Participants — p=0.8325
Insulin Resistance · Obesity
Primary: Insulin Sensitivity — -3.8; 0.9 µmol/kgFFM/min
Down Syndrome · Alopecia Areata · Atopic Dermatitis / Eczema
Primary: Number of Serious Adverse Events (SAE) Definitely Related to Tofacitinib Treatment. — 0 Serious Adverse Events
Anxiety · Social Anxiety Disorder · Panic Disorder
Primary: Change in Prefrontal Cortex (PFC) Activity (Baseline to Transfer Run) From the Reappraise > Look Contrast on the Emotion Regulation Task (ERT) — 0.042; 0.019; 0.007…
Physical Inactivity
Primary: Process Outcome - Advisory Committee Members Accept Invitation — 1 Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Repaglinide — 9.409; 26.87…
Asthma · Obesity
Primary: Change in Airway Reactivity — 0; -0.8 μg methacholine — p=0.81
Ovarian Cancer
Primary: CA-125 Response Rate — 0 Participants
Approach/Avoidance Behavior
Primary: Reaction Times in the Approach/Avoidance Test — 36.8; 12.4 milliseconds
Social Anxiety Disorder
Primary: Trial-level Bias Score (Negative) — -54.92; -48.45; -44.29; -46.07 Milliseconds
Breast Cancer
Primary: Quality of Life of the Patients at 12 Months — 59 score on a scale
Infections · Vector Borne Diseases · Systemic Inflammatory Response Syndrome
Primary: Emax — 0.35 Maximum clearance rate (1/hour)
Depression in Adolescence
Primary: BDI-II -Pretest — 12.54; 14.42 score on a scale
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Number of Participants With Response — 1; 4; 5; 3 Participants
Invasive Breast Cancer
Primary: Correlation Coefficient Between FFNP Uptake and Allred Score — 0.3215 correlation coefficient (rho) — p=0.1347